808 related articles for article (PubMed ID: 25445694)
1. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
2. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells.
Sun R; Shen S; Zhang YJ; Xu CF; Cao ZT; Wen LP; Wang J
Biomaterials; 2016 Oct; 103():44-55. PubMed ID: 27376558
[TBL] [Abstract][Full Text] [Related]
4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
5. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics.
Wu FL; Li RT; Yang M; Yue GF; Wang HY; Liu Q; Cui FB; Wu PY; Ding H; Yu LX; Qian XP; Liu BR
Cancer Lett; 2015 Jul; 363(1):7-16. PubMed ID: 25592042
[TBL] [Abstract][Full Text] [Related]
6. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Vijayaraghavalu S; Labhasetwar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019
[TBL] [Abstract][Full Text] [Related]
7. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
8. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
9. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
Croker AK; Allan AL
Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
[TBL] [Abstract][Full Text] [Related]
11. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
Farnie G; Sotgia F; Lisanti MP
Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW
Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.
Pervin S; Hewison M; Braga M; Tran L; Chun R; Karam A; Chaudhuri G; Norris K; Singh R
PLoS One; 2013; 8(1):e53287. PubMed ID: 23341935
[TBL] [Abstract][Full Text] [Related]
15. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
16. Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics.
Su X; Wang Z; Li L; Zheng M; Zheng C; Gong P; Zhao P; Ma Y; Tao Q; Cai L
Mol Pharm; 2013 May; 10(5):1901-9. PubMed ID: 23570548
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells.
Sun R; Liu Y; Li SY; Shen S; Du XJ; Xu CF; Cao ZT; Bao Y; Zhu YH; Li YP; Yang XZ; Wang J
Biomaterials; 2015 Jan; 37():405-14. PubMed ID: 25453968
[TBL] [Abstract][Full Text] [Related]
18. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.
Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P
Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.
Li Y; Zhang T; Korkaya H; Liu S; Lee HF; Newman B; Yu Y; Clouthier SG; Schwartz SJ; Wicha MS; Sun D
Clin Cancer Res; 2010 May; 16(9):2580-90. PubMed ID: 20388854
[TBL] [Abstract][Full Text] [Related]
20. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
